Harvard Archives - Medical Design Sourcing

Researchers develop implantable heart valve that grows with a child

The FibraValve is composed of long filaments of polymer fibers, which replicate the physical properties of a human heart valve and are porous enough to allow cells to infiltrate and replace the scaffold with living tissue. Credit: Wyss Institute at Harvard University

A research team at the Wyss Institute and Harvard’s John A. Paulson School of Engineering and Applied Sciences (SEAS) say they developed a heart valve that can grow with a child, minimizing surgical complications and suffering.

This research team developed a nanofiber fabrication technique to rapidly manufacture heart valves with regenerative and growth potential. They began their work in 2014 and touted the potential of this technology as far back as 2017.

The team described the steps taken in a new paper published in Matter. They say they can manufacture their next-generation synthetic heart valve — FibraValve — in less than 10 minutes…

They said it at DeviceTalks Boston

Proximie CEO Nadine Hachach-Haram [Photo courtesy of Proximie]Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead.

Here are some of the most quotable insights from panelists and speakers at our live event.

And make sure to save the date — and save your seat — for DeviceTalks West in Santa Clara, California on Oct. 19 and 20.

Get the full story at our sister site, Medical Design & Outsourcing.

They said it at DeviceTalks Boston

Proximie CEO Nadine Hachach-Haram [Photo courtesy of Proximie]

Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead.

Here are some of the most quotable insights from panelists and speakers at our live event.

And make sure to save the date — and save your seat — for DeviceTalks West in Santa Clara, California on Oct. 19 and 20.

Read on to hear what medtech leaders had to say at DeviceTalks Boston 2022.

Next >>

Here’s where Harvard’s engineering dean sees medtech research going

Harvard University constructed a 500,000-square-foot Science and Engineering Complex (SEC) for SEAS in Boston’s Allston neighborhood in 2020. [Image courtesy of Harvard SEAS]

Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited.

Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it comes to medtech innovation.

Doyle noted that the school he runs has 5% of the faculty — and produces 40% of the startups out of Harvard.

Get the full story at our sister site, MassDevice.

Discover where this artificial pancreas pioneer sees medtech development going

Frank Doyle — a prolific medical device inventor and Harvard engineering school leader — will discuss the future of medtech development during DeviceTalks Boston, May 10–11, 2022.

A pioneer in developing artificial pancreas technology to treat diabetes, Doyle will share his insights on the future of medical device development, including the expanding role of robotics and artificial intelligence.

(Register today!)

Doyle is the Dean of the Harvard John A. Paulson School of Engineering and Applied Sciences. His success earned him election into the National Academy of Engineering last year (and National Academies of Medicine and Inventors before that).

Doyle will hit upon several critical areas during his keynote presentation at DeviceTalks Boston including:

What lessons he learned from the many years spent developing the complicated systems and algorithms of an artificial pancreas and providing the support necessary to bring it to market. How, i…

Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes

The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms.

In an effort to accelerate efforts to mine genetic data for insights into mechanisms, and eventually rationally designed treatments, the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based at the Broad Institute in Cambridge, Massachusetts.

Get the full story at our sister site, Drug Delivery Business News.